US2018296647A1PendingUtilityA1

Prophylactic and therapeutic agent for rett syndrome (rtt) comprising ghrelin as active ingredient

Assignee: UNIV KURUMEPriority: Oct 14, 2015Filed: Apr 20, 2016Published: Oct 18, 2018

Est. expiryOct 14, 2035(~9.2 yrs left)· nominal 20-yr term from priority

Inventors:Toyojiro Matsuishi Masayasu Kojima Kotaro Yuge Munetsugu Hara Yushiro Yamashita

A61K 38/22A61P 25/00

PatentIndex Score

Cited by

References

Claims

Abstract

A prophylactic and therapeutic agent for Rett Syndrome (RTT) is provided, a pharmaceutical composition comprising ghrelin and a pharmaceutically acceptable carrier and a prophylactic and therapeutic agent for RTT comprising a therapeutically effective amount of ghrelin. The side chain of serine at the 3rd position of ghrelin is modified with octanoic acid.

Claims

exact text as granted — not AI-modified

1 . A pharmaceutical composition comprising ghrelin and a pharmaceutically acceptable carrier. 
     
     
         2 . The pharmaceutical composition according to  claim 1  wherein the side chain of serine at the 3rd position of ghrelin is modified with octanoic acid. 
     
     
         3 . A prophylactic and therapeutic agent for Rett Syndrome (RTT) comprising a therapeutically effective amount of ghrelin. 
     
     
         4 . The prophylactic and therapeutic agent according to  claim 3  wherein the side chain of serine at the 3rd position of ghrelin is modified with octanoic acid.

Join the waitlist — get patent alerts

Track US2018296647A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.